Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results